All data are based on the daily closing price as of December 24, 2024
m

Medy-Tox

086900.KQ
86.08 USD
-0.84
-0.97%

Overview

Last close
86.08 usd
Market cap
575.99M usd
52 week high
230.88 usd
52 week low
82.94 usd
Target price
143.92 usd

Valuation

P/E
N/A
Forward P/E
19.3424
Price/Sales
3.4076
Price/Book Value
1.7109
Enterprise Value
615.30M usd
EV/Revenue
3.7185
EV/EBITDA
21.2701

Key financials

Revenue TTM
168.76M usd
Gross Profit TTM
86.38M usd
EBITDA TTM
25.83M usd
Earnings per Share
N/A usd
Dividend
3.02 usd
Total assets
613.94B usd
Net debt
N/A usd

About

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.
  • Symbol
    086900.KQ
  • Exchange
    KQ
  • Isin
    KR7086900008
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
    Mr. Hyun-Ho Jung
  • Headquarter
    Cheongju
  • Web site
    https://www.medy-tox.co.kr
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top